CN102448979B - 纯化重组促卵泡激素的方法 - Google Patents
纯化重组促卵泡激素的方法 Download PDFInfo
- Publication number
- CN102448979B CN102448979B CN201080022681.1A CN201080022681A CN102448979B CN 102448979 B CN102448979 B CN 102448979B CN 201080022681 A CN201080022681 A CN 201080022681A CN 102448979 B CN102448979 B CN 102448979B
- Authority
- CN
- China
- Prior art keywords
- chromatography
- anion
- exchange
- stimulating hormone
- exchange chromatography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 title claims abstract description 143
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 title claims abstract description 143
- 229940028334 follicle stimulating hormone Drugs 0.000 title claims abstract description 142
- 238000000034 method Methods 0.000 title claims abstract description 93
- 238000005571 anion exchange chromatography Methods 0.000 claims abstract description 56
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims abstract description 52
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 37
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 30
- 239000007788 liquid Substances 0.000 claims abstract description 15
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims abstract description 12
- 238000004271 weak anion exchange chromatography Methods 0.000 claims abstract description 10
- 239000011347 resin Substances 0.000 claims description 51
- 229920005989 resin Polymers 0.000 claims description 51
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 27
- 238000005277 cation exchange chromatography Methods 0.000 claims description 25
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 21
- 229920002684 Sepharose Polymers 0.000 claims description 19
- 238000000108 ultra-filtration Methods 0.000 claims description 16
- 239000012609 strong anion exchange resin Substances 0.000 claims description 15
- 108010081934 follitropin beta Proteins 0.000 claims description 13
- 239000011159 matrix material Substances 0.000 claims description 12
- 238000001728 nano-filtration Methods 0.000 claims description 10
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 10
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 9
- 125000002091 cationic group Chemical group 0.000 claims description 9
- 125000000524 functional group Chemical group 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 6
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 150000001768 cations Chemical class 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 3
- 229910021645 metal ion Inorganic materials 0.000 claims description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- JQYMGXZJTCOARG-UHFFFAOYSA-N Reactive blue 2 Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S(O)(=O)=O)=C1 JQYMGXZJTCOARG-UHFFFAOYSA-N 0.000 claims description 2
- 230000021523 carboxylation Effects 0.000 claims description 2
- 238000006473 carboxylation reaction Methods 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 239000012475 sodium chloride buffer Substances 0.000 claims 2
- 239000012619 Butyl Sepharose® Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 13
- 238000011282 treatment Methods 0.000 abstract description 10
- 238000002360 preparation method Methods 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 229940088597 hormone Drugs 0.000 description 27
- 239000005556 hormone Substances 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 26
- 239000012528 membrane Substances 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 239000003463 adsorbent Substances 0.000 description 16
- 238000013016 damping Methods 0.000 description 16
- 239000012530 fluid Substances 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 10
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 210000001672 ovary Anatomy 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 9
- 230000004071 biological effect Effects 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 8
- 229940057854 gonal f Drugs 0.000 description 8
- 150000007523 nucleic acids Chemical group 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- 241000699802 Cricetulus griseus Species 0.000 description 7
- 108010006578 follitropin alfa Proteins 0.000 description 7
- 230000013595 glycosylation Effects 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000002594 sorbent Substances 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 101001038874 Homo sapiens Glycoprotein hormones alpha chain Proteins 0.000 description 5
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical compound [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 5
- 150000001450 anions Chemical class 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 238000005341 cation exchange Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000011210 chromatographic step Methods 0.000 description 5
- 238000011026 diafiltration Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002349 favourable effect Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 229920006393 polyether sulfone Polymers 0.000 description 5
- 239000004627 regenerated cellulose Substances 0.000 description 5
- 239000013017 sartobind Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 4
- 239000012505 Superdex™ Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 210000002394 ovarian follicle Anatomy 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- YKCWQPZFAFZLBI-UHFFFAOYSA-N cibacron blue Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC=C1S(O)(=O)=O YKCWQPZFAFZLBI-UHFFFAOYSA-N 0.000 description 3
- -1 dimethyl aminoethyl Chemical group 0.000 description 3
- 238000002086 displacement chromatography Methods 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 230000005661 hydrophobic surface Effects 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 230000021595 spermatogenesis Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 2
- 239000007994 TES buffer Substances 0.000 description 2
- 239000007997 Tricine buffer Substances 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000012930 cell culture fluid Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940015047 chorionic gonadotropin Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 229960004418 trolamine Drugs 0.000 description 2
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 1
- 229920006310 Asahi-Kasei Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102100040796 Glycoprotein hormones alpha chain Human genes 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 150000008536 L-asparagines Chemical class 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010003883 azoospermia Diseases 0.000 description 1
- 102000035824 beta Subunit Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010081485 beta Subunit Follicle Stimulating Hormone Proteins 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012504 chromatography matrix Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 210000004368 gonadotroph Anatomy 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 208000008634 oligospermia Diseases 0.000 description 1
- 230000036616 oligospermia Effects 0.000 description 1
- 231100000528 oligospermia Toxicity 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- 238000002305 strong-anion-exchange chromatography Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09157133.1 | 2009-04-01 | ||
| EP09157133 | 2009-04-01 | ||
| PCT/EP2010/002111 WO2010115586A2 (en) | 2009-04-01 | 2010-04-01 | Method for purifying recombinant fsh |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102448979A CN102448979A (zh) | 2012-05-09 |
| CN102448979B true CN102448979B (zh) | 2015-03-04 |
Family
ID=42153744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080022681.1A Active CN102448979B (zh) | 2009-04-01 | 2010-04-01 | 纯化重组促卵泡激素的方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US9096683B2 (enExample) |
| EP (1) | EP2414380B1 (enExample) |
| JP (2) | JP5845170B2 (enExample) |
| KR (1) | KR101761168B1 (enExample) |
| CN (1) | CN102448979B (enExample) |
| AU (1) | AU2010234028B2 (enExample) |
| BR (1) | BRPI1012647B1 (enExample) |
| CA (1) | CA2755927A1 (enExample) |
| CY (1) | CY1116963T1 (enExample) |
| DK (1) | DK2414380T3 (enExample) |
| EA (1) | EA028065B1 (enExample) |
| ES (1) | ES2552055T3 (enExample) |
| HR (1) | HRP20151086T1 (enExample) |
| HU (1) | HUE025959T2 (enExample) |
| IL (1) | IL215234A (enExample) |
| ME (1) | ME02277B (enExample) |
| MX (1) | MX2011010480A (enExample) |
| NZ (1) | NZ595661A (enExample) |
| PL (1) | PL2414380T3 (enExample) |
| PT (1) | PT2414380E (enExample) |
| RS (1) | RS54318B1 (enExample) |
| SI (1) | SI2414380T1 (enExample) |
| SM (1) | SMT201500276B (enExample) |
| UA (1) | UA106369C2 (enExample) |
| WO (1) | WO2010115586A2 (enExample) |
| ZA (1) | ZA201106800B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2755927A1 (en) * | 2009-04-01 | 2010-10-14 | Biogenerix Ag | Method for purifying recombinant fsh |
| CN103570820B (zh) * | 2012-08-06 | 2015-11-18 | 齐鲁制药有限公司 | 一种重组人促卵泡激素的纯化方法 |
| KR101516054B1 (ko) * | 2012-11-21 | 2015-05-06 | 씨제이헬스케어 주식회사 | 신규한 지속형 인간 성장호르몬 단량체를 제조하는 방법 |
| CN103059125B (zh) * | 2012-12-27 | 2015-08-12 | 浙江海正药业股份有限公司 | 重组人促卵泡激素的纯化方法 |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| CN103539861B (zh) * | 2013-11-01 | 2015-02-18 | 广州联康生物科技有限公司 | 长效重组人促卵泡激素融合蛋白 |
| CN103539860B (zh) * | 2013-11-01 | 2014-12-03 | 广州优联康医药科技有限公司 | 一种长效重组人促卵泡激素融合蛋白 |
| AR100131A1 (es) * | 2014-04-18 | 2016-09-14 | Cadila Healthcare Ltd | Proceso de purificación de gonadotropina |
| CN104479005B (zh) * | 2014-09-05 | 2017-10-31 | 上海丽珠制药有限公司 | 一种促性腺激素纯化的方法 |
| CN105461799A (zh) * | 2015-12-31 | 2016-04-06 | 哈药集团技术中心 | 一种重组人促卵泡生成素的纯化方法 |
| CN106117342B (zh) * | 2016-07-07 | 2020-01-03 | 江西浩然生物医药有限公司 | 一种高纯度尿促卵泡素的制备方法 |
| RU2694598C1 (ru) * | 2018-08-07 | 2019-07-16 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Клеточная линия huFSHKKc6 - продуцент рекомбинантного человеческого фолликулостимулирующего гормона (ФСГ) и способ получения ФСГ с использованием данной линии |
| MX2022007638A (es) * | 2019-12-26 | 2022-07-19 | Lg Chemical Ltd | Procedimiento de purificacion de la hormona foliculoestimulante. |
| KR102283871B1 (ko) * | 2021-03-02 | 2021-08-02 | 한국원자력연구원 | 크로마토그래피를 이용한 무담체 홀뮴-166의 분리 방법, 분리 장치 및 이에 의하여 분리된 무담체 홀뮴-166 |
| CN113372433B (zh) * | 2021-03-12 | 2022-10-11 | 上海景泽生物技术有限公司 | 纯化fsh方法 |
| CN114591414A (zh) * | 2022-03-24 | 2022-06-07 | 江西浩然生物制药有限公司 | 一种人绒毛膜促性腺激素的制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4840896A (en) | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
| US6455282B1 (en) * | 1983-11-02 | 2002-09-24 | Genzyme Corporation | Cells, vectors and methods for producing biologically active TSH |
| US4923805A (en) | 1983-11-02 | 1990-05-08 | Integrated Genetics, Inc. | Fsh |
| IT1206302B (it) | 1987-06-26 | 1989-04-14 | Serono Cesare Ist Ricerca | Ormone follicolo-stimolante urinario |
| CA2018676C (en) | 1989-06-20 | 2003-05-06 | Christie A. Kelton | Novel heteropolymeric protein production methods |
| US5021160A (en) * | 1990-01-09 | 1991-06-04 | Gelman Sciences, Inc. | Strongly acidic microporous membranes for cation exchange |
| DE4440587A1 (de) | 1994-11-14 | 1996-05-15 | Fliether Karl Gmbh & Co | Basquill-Schloß |
| US6261823B1 (en) * | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
| PT996629E (pt) | 1997-06-25 | 2006-12-29 | Applied Research Systems | Análogos de hormonas glicoproteicas reticulados com ligações dissulfito, sua preparação e utilização |
| US5990288A (en) * | 1997-10-21 | 1999-11-23 | Vitro Diagnostics, Inc. | Method for purifying FSH |
| US6414123B1 (en) * | 1997-10-21 | 2002-07-02 | Vitro Diagnostics, Inc. | Method for purifying FSH |
| EP1169349B1 (en) | 1999-04-16 | 2007-03-28 | Instituto Massone S.A. | Process for preparing gonadotropin compositions |
| WO2001058493A1 (en) | 2000-02-11 | 2001-08-16 | Maxygen Aps | Conjugates of follicle stimulating hormones |
| US7157277B2 (en) * | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
| CA2483650A1 (en) | 2002-05-31 | 2003-12-11 | E.I. Du Pont De Nemours And Company | Copolymers having tunable energy levels and color of emission |
| PT1610822E (pt) | 2003-04-02 | 2011-01-05 | Ares Trading Sa | Formulações farmacêuticas líquidas ou liofilizadas de fsh e/ou lh em conjunto com o surfactante não iónico poloxâmero 188 e um agente bacteriostático |
| ES2333128T3 (es) * | 2003-12-22 | 2010-02-17 | Ares Trading S.A. | Metodo para purificar fsh. |
| SI1809663T1 (sl) * | 2004-11-09 | 2009-02-28 | Ares Trading Sa | Postopek za äśiĺ äśenje fsh |
| US8604175B2 (en) * | 2005-12-09 | 2013-12-10 | Ares Trading S.A. | Method for purifying FSH or a FSH mutant |
| ES2572629T3 (es) * | 2005-12-09 | 2016-06-01 | Ares Trading S.A. | Método para purificar FSH o un mutante de FSH |
| PT2170942E (pt) * | 2007-06-28 | 2013-10-22 | Biogenerix Ag | Clone celular produtor de fsh |
| AR067536A1 (es) * | 2007-07-17 | 2009-10-14 | Hoffmann La Roche | Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea |
| CA2755927A1 (en) * | 2009-04-01 | 2010-10-14 | Biogenerix Ag | Method for purifying recombinant fsh |
-
2010
- 2010-04-01 CA CA2755927A patent/CA2755927A1/en not_active Abandoned
- 2010-04-01 AU AU2010234028A patent/AU2010234028B2/en not_active Ceased
- 2010-04-01 ME MEP-2015-172A patent/ME02277B/me unknown
- 2010-04-01 CN CN201080022681.1A patent/CN102448979B/zh active Active
- 2010-04-01 KR KR1020117025974A patent/KR101761168B1/ko not_active Expired - Fee Related
- 2010-04-01 UA UAA201112796A patent/UA106369C2/ru unknown
- 2010-04-01 HU HUE10713424A patent/HUE025959T2/en unknown
- 2010-04-01 DK DK10713424.9T patent/DK2414380T3/en active
- 2010-04-01 RS RS20150682A patent/RS54318B1/sr unknown
- 2010-04-01 PT PT107134249T patent/PT2414380E/pt unknown
- 2010-04-01 JP JP2012502514A patent/JP5845170B2/ja not_active Expired - Fee Related
- 2010-04-01 BR BRPI1012647-3A patent/BRPI1012647B1/pt not_active IP Right Cessation
- 2010-04-01 HR HRP20151086TT patent/HRP20151086T1/hr unknown
- 2010-04-01 WO PCT/EP2010/002111 patent/WO2010115586A2/en not_active Ceased
- 2010-04-01 EA EA201171199A patent/EA028065B1/ru not_active IP Right Cessation
- 2010-04-01 PL PL10713424T patent/PL2414380T3/pl unknown
- 2010-04-01 EP EP10713424.9A patent/EP2414380B1/en active Active
- 2010-04-01 SI SI201031050T patent/SI2414380T1/sl unknown
- 2010-04-01 US US13/262,622 patent/US9096683B2/en not_active Expired - Fee Related
- 2010-04-01 NZ NZ595661A patent/NZ595661A/xx not_active IP Right Cessation
- 2010-04-01 ES ES10713424.9T patent/ES2552055T3/es active Active
- 2010-04-01 MX MX2011010480A patent/MX2011010480A/es unknown
-
2011
- 2011-09-15 ZA ZA2011/06800A patent/ZA201106800B/en unknown
- 2011-09-19 IL IL215234A patent/IL215234A/en active IP Right Grant
-
2015
- 2015-06-15 US US14/739,935 patent/US20150353599A1/en not_active Abandoned
- 2015-09-09 JP JP2015177674A patent/JP6231056B2/ja not_active Expired - Fee Related
- 2015-10-30 CY CY20151100971T patent/CY1116963T1/el unknown
- 2015-11-04 SM SM201500276T patent/SMT201500276B/it unknown
-
2016
- 2016-07-01 US US15/200,714 patent/US20160304575A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102448979B (zh) | 纯化重组促卵泡激素的方法 | |
| JP7407161B2 (ja) | アリールスルファターゼａの精製方法 | |
| EP3960854B1 (en) | Large-scale production of soluble hyaluronidase | |
| EP3464331B1 (en) | Stabilized pre-fusion rsv f proteins | |
| JP5728016B2 (ja) | 組換えヒトエリスロポエチン（ｅｐｏ）を精製するためのプロセス、このようにして精製されたｅｐｏおよびこれを含む医薬組成物 | |
| JP2009273427A (ja) | 組換え体ヒトｆｓｈの製造方法 | |
| CZ20031157A3 (en) | Method of purification of interferon-beta | |
| CN102056940A (zh) | 纯化促红细胞生成素的方法 | |
| CN110563832B (zh) | 一种高纯度重组促卵泡刺激素纯化方法 | |
| JP5750471B2 (ja) | 組換え体ヒトｆｓｈの製造方法 | |
| JP2011172602A (ja) | 組換え体ヒトｆｓｈの製造方法 | |
| HK1164935B (en) | Method for purifying the rabies virus | |
| HK1164935A1 (en) | Method for purifying the rabies virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: RATIOPHARM GMBH Free format text: FORMER OWNER: BIOGENERIX AG Effective date: 20140723 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20140723 Address after: Ulm Applicant after: RATIOPHARM GmbH Address before: Mannheim Applicant before: Biogenerix AG Effective date of registration: 20140723 Address after: Mannheim Applicant after: BIOGENERIX AG Address before: Mannheim Applicant before: Biogenerix AG |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180611 Address after: London, England Patentee after: Ty Hamax Headquarters UK Ltd. Address before: Ulm Patentee before: Ratiopharm GmbH |
|
| TR01 | Transfer of patent right |